
    
      The secondary objectives of this study are to measure changes in the following between 0 and
      8 weeks after injection:

      A. vaginal flora and Nugent score.

      B. vaginal pH.

      C. functional evolution via the VHI index by Gloria Bachman (state of the vaginal mucosa),
      pain / dyspareunia (visual analog scale) and the satisfaction concerning care viay the PGI-I
      questionnaire (Patient Global Impression and Improvement).

      D. Procollagen I and III gene expression (by PCR) and mitotic activity of the mucosa (Ki67
      proliferation marker) based on biopsies.
    
  